Neurofibromatosis 2 (NF2) is a rare genetic disorder that is primarily characterized by noncancerous (benign) tumors of the nerves that transmit balance and sound impulses from the inner ears to the brain (bilateral acoustic neuromas/vestibular schwannomas). NF Biosolutions is partnering with CBTN on biobanking and research efforts to discover the underlying causes and identification of potential treatments through molecular analysis.
Evaluation of Drug Vulnerability of NF2 Tumor Models
Neurofibromatosis type 2 (NF2) tumors are very rare and understudied tumors. Using high quality specimens provided by the Children’s Brain Tumor Network, researchers will run broad drug interaction experiments in an effort to identify treatments for this rare tumor.
Pre-clinical Studies for NF2 Schwannomas
There is a great need for pharmaceuticals that can treat NF2 tumors. Using specimens made available through the Children’s Brain Tumor Network, researchers look to support clinical trial research through the identification of NF2 drug targets.
Biomarker Identification for Neurofibromatosis Type 2 Background
The identification of biomarkers related to NF2-associated brain tumors such as schwannomas, meningiomas, and ependymomas could lead to advancements in research and treatment. Using tumor tissues provided by the Children’s Brain Tumor Network, researchers hope to identify new avenues for treatment.
CDC42 RHOJ Interaction Inhibitors for the Treatment of Neurofibromatosis
Neurofibromatosis type 2 (NF2) tumors can cause significant hearing loss and current therapies can accelerate this loss through the impact of side effects and non compliance. Using cell lines provided by the Children’s Brain Tumor Network, researchers are testing new treatments to address this issue.